HALO News and Press, Halozyme Therapeutics Inc. From 08/09/20

Halozyme Therapeutics (NASDAQ: HALO ) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. The consensus EPS Estimate is $0.24  vs. -$0.10 in 2Q19 and the consensus Revenue Estimate is $65.81M (+68.1% Y/Y). Over the last 2 years, HALO has beaten...

SAN DIEGO , Aug. 4, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive officer, will participate in the upcoming Canaccord Genuity 40th Annual Growth Conference. Dr. Torley will take part in a firesid...

Health Canada has approved a subcutaneous formulation of Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceutical Companies' multiple myeloma med Darzalex (daratumumab), originally approved for intravenous administration. More news on: Johnson & Johnson, Genmab A/S, Halozyme ...

SAN DIEGO , July 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2020 on Monday, August 10 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will lea...

Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...

( Pexels ) Of all the investable sectors and industries, one of the top-performing over the past few months is biotechnology. Since its March low (18 th ), the SPDR Biotech ETF ( XBI ) has risen about 75% as investors speculate on virus treatment and vaccine rumors. Understandably, many in...

When it comes to stock market valuations, the rich seem to be getting even richer. More news on: iShares Russell 1000 Growth ETF, iShares Russell 1000 Value ETF, Halozyme Therapeutics, Inc., News on ETFs Read more ...

I have always stuck up for Western medicine. You can chew all the celery you want, but without antibiotics, three quarters of us would not be here . ~ Hugh Laurie The prospects of Halozyme Therapeutics (HALO) look exciting, but its negative cash flows from operations and stock repurchases...

SAN DIEGO , June 29, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, a fixed-dose combination (FDC) of Perjeta ...

The FDA approves Roche ( OTCQX:RHHBY -0.6% ) unit Genentech's subcutaneously administered Phesgo (pertuzumab, trastuzumab and hyaluronidase- zzxf) for adults with metastatic HER2-positive breast cancer and adults with early-stage HER2-positive breast cancer. More news on: Roche Holding...